Reducing The Time And Cost Of Robust Analytical Method Development For Cell Therapy Programs Using A Design-Of-Experiment (DoE) Approach

By Patrick Kellish, Danielle Kling, Richard Smindak, Roger Herr, and Bruce Thompson, Kincell Bio

Developing robust analytical assays is crucial for ensuring the identity, potency, and safety of complex cell therapies. Traditional method development typically relies on one-factor-at-a-time experimentation. This inefficient route fails to identify critical interactions between variables, often leading to unoptimized, fragile assays that slow down commercialization timelines.

Adopting a statistical design-of-experiment (DOE) approach allows researchers to evaluate multiple factors simultaneously. This systematic methodology establishes a well-defined method design space with minimal physical experimentation, dramatically accelerating development timelines while conserving precious raw materials and analyst resources. Real-world applications—such as optimizing potency readouts and multi-functional cell proliferation assays—demonstrate that this structured framework compresses months of traditional development into mere weeks.

Transitioning to advanced statistical workflows mitigates the risk of unexpected regulatory delays and provides deeper process understanding. Explore the complete technical article to learn how statistical optimization can elevate assay quality and accelerate clinical timelines.